Stanford Researchers Publish Seminal Paper on Use of 10x Genomics’ GemCode™ Technology for Genomic Analysis

10x Genomics today announced the publication of a study in Nature Biotechnology on theGemCode™ technology platform, a powerful approach that enables researchers to discover previously inaccessible genomic information, providing key insights into heritable disease and cancer genetics.
According to the press release:

The microfluidics-based, Linked-Read sequencing technology, built on the proprietary GemCode™ platform, can phase and haplotype germline and cancer genomes using only nanograms of input DNA. This droplet-based system prepares barcoded libraries for short-read sequencing and computationally reconstructs long-range haplotype and structural variant information. This report demonstrates the utility of the GemCode platform for generating haplotype blocks and phasing a set of structural variants, as well as resolving the structure of a gene fusion in a cancer cell line using phased exome sequencing. The article describes the first genome-scale haplotype analysis of a primary tumor derived from a clinical sample, thus revealing a series of novel features not apparent with standard whole genome sequencing approaches.

Serge Saxonov, Ph.D., Chief Executive Officer of 10x Genomics commented:

Our GemCode technology has been adopted for use in multiple applications, including whole-genome phasing and structural variant analysis, de novo genome assembly, remapping of difficult regions of the genome, and dynamic gene expression of single cells. We are providing tools for researchers to understand the genetic basis of disease at unprecedented levels, which will ultimately lead to transformative advancements in patient care.

Click here to view the full press release.